Use of proteomic analysis to monitor responses to biological therapies

Expert Opinion on Biological Therapy

Volumn 4, Issue 1, 2004, Pages 83-93

  Espina, Virginia ^a   Dettloff, Kristine A ^b   Cowherd, Stacy ^a   Petricoin III, Emanuel F ^c   Liotta, Lance A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Biomarker; Cancer; Individualised therapy; Laser capture microdissection; Mass spectrometry; Protein microarray; Proteomics; SELDI TOF

Indexed keywords

BIOLOGICAL MARKER;

APOPTOSIS; BIOINFORMATICS; BIOLOGICAL THERAPY; CANCER THERAPY; CELL ISOLATION; CELL SURVIVAL; DISEASE COURSE; GENOMICS; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; OVARY CANCER; PATHOGENESIS; PATIENT CARE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY; TREATMENT OUTCOME;

ANIMALS; COMPUTATIONAL BIOLOGY; HUMANS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; SIGNAL TRANSDUCTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 0346726217     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.1.83     Document Type: Review

References (95)

1. LI J, ZHANG Z, ROSENZWEIG J, WANG YY, CHAN DW: Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. (2002) 8:1296-1304. Identified three potential biomarkers for breast cancer via SELDI mass spectrometry.
2. STETSON SJ, PEREZ-VERDIA A, MAZUR W et al.: Cardiac hypertrophy after transplantation is associated with persistent expression of tumor necrosis factor-alpha. Circulation (2001) 6:676-681.
3. DOMENECH N, CRESPO-LEIRO MG, MOSCOSO I et al.: Neither acute rejection nor immunosuppressant drug therapy (cyclosporine or tacrolimus) correlates with expression of either CD40 or CD154 on peripheral blood cells among human cardiac transplant patients. Transplant. Proc. (2003) 5:1994-1995.
4. CELIS JE, GROMOV P: Proteomics in translational cancer research: toward an integrated approach. Cancer Cell (2003) 1:9-15.
5. CHEN G, GHARIB TG, HUANG CC et al: Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin. Cancer Res. (2002) 7:2298-2305.
6. DELEHANTY JB, LIGLER FS: A microarray immunoassay for simultaneous detection of proteins and bacteria. Anal. Chem. (2002) 21:5681-5687.
7. PANDEY A, MANN M: Proteomics to study genes and genomes. Nature (2000) 6788:837-846.
8. ISSAQ HJ, VEENSTRA TD, CONRADS TP, FELSCHOW D: The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem. Biophys. Res. Commun. (2002) 3:587-592.
9. WULFKUHLE JD, SGROI DC, KRUTZSCH H et al: Proteomics of human breast ductal carcinoma in situ. Cancer Res. (2002) 22:6740-6749.
10. VENTER JC, ADAMS MD, MYERS EW et al.: The sequence of the human genome. Science (2001) 5507:1304-1351. Description of complexity of the human genome.
11. EMMERT-BUCK MR, STRAUSBERG RL, KRIZMAN DB et al.: Molecular profiling of clinical tissue specimens: feasibility and applications. Am. J. Pathol. (2000) 4:1109-1115.
12. KNEZEVIC V, LEETHANAKUL C, BICHSEL VE et al.: Proteomic profiling of the cancer microenvironment by antibody arrays. Proteomics (2001) 10:1271-1278. Differential protein expression in stromal cells in the vicinity of oral squamous cell cancer correlated with tumour progression.
13. LIOTTA L, PETRICOIN E: Molecular profiling of human cancer. Nat. Rev. Genet. (2000) 1:48-56. Combination of genomic and proteomic profiling for effective monitoring of biological response.
14. PAWELETZ CP, TROCK B, PENNANEN M et al: Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis. Markers (2001) 4:301-307.
15. PAWELETZ CP, CHARBONEAU L, BICHSEL VE et al: Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene (2001) 16:1981-1989. Demonstrated utility of protein microarrays; in prostate cancer profiling.
16. PETRICOIN EF 3RD, ORNSTEIN DK, PAWELETZ CP et al.: Serum proteomic patterns for detection of prostate cancer. J. Natl. Cancer Inst. (2002) 20:1576-1578. Predicted prostate cancer by serum protein profiling using SELDI mass spectrometry for patients with PSA levels > 4 ng/ml.
17. PETRICOIN EF, ARDEKANI AM, HITT BA et al: Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 9306:572-577. Serum proteomic patterns generated by SELDI mass spectrometry correctly clustered sera from patients with ovarian cancer with 100% sensitivity and 95% specificity as compared with normal sera.
18. CLARKE W, SILVERMAN BC, ZHANG Z et al: Characterization of renal allograft rejection by urinary proteomic analysis. Ann. Surg. (2003) 5:660-664; discussion 664-665. Identified five urine biomarkers for distinguishing renal allograft rejection with 83% sensitivity and 100% specificity.
19. URBANOWSKA T, MANGIALAIO S, HARTMANN C, LEGAY F: Development of protein microarray technology to monitor biomarkers of rheumatoid arthritis disease. Cell Biol. Toxicol. (2003) 3:189-202.
20. CARRETTE O, DEMALTE I, SCHERL A et al.: A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics (2003) 8:1486-1494.
21. SHIPP MA, ROSS KN, TAMAYO P et al: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. (2002) 1:68-74.
22. SINGH D, FEBBO PG, ROSS K et al: Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 2:203-209.
23. SCHWARTZ DR, KARDIA SL, SHEDDEN KA et al: Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. (2002) 16:4722-4729.
24. SORLIE T, PEROU CM, TIBSHIRANI R et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad Sci. USA (2001) 19:10869-10874.
25. STAUDT LM: Gene expression profiling of lymphoid malignancies. Annu. Rev. Med. (2002) 53:303-318.
26. PEGORARO L, PALUMBO A, ERIKSON J et al: A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia. Proc. Natl. Acad Sci. USA (1984) 22:7166-7170.
27. REED JC, HALDAR S, CUDDY MP, CROCE C, MAKOVER D: Deregulated BCL2 expression enhances growth of a human B cell line. Oncogene (1989) 9:1123-1127.
28. KINGSMORE SF, PATEL DD: Multiplexed protein profiling on antibody-based microarrays by rolling circle amplification. Curr Opin. Biotechnol. (2003) 1:74-81.
29. LIOTTA LA, KOHN EC, PETRICOIN EF: Clinical proteomics: personalized molecular medicine. JAMA (2001) 18:2211-2214. Discussion of protein-targeted therapy and proteomic profiling for individualised therapy.
30. LIOTTA LA, ESPINA V, MEHTA AI et al: Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell (2003) 4:317-325. In-depth discussion of technical aspects of protein microarrays for clinical applications.
31. MANN M, HENDRICKSON RC, PANDEY A: Analysis of proteins and proteomes by mass spectrometry. Annu. Rev. Biochem. (2001) 70:437-473.
32. PETRICOIN EF, ZOON KC, KOHN EC, BARRETT JC, LIOTTA LA: Clinical proteomics: translating benchside promise into bedside reality. Nat. Rev. Drug Discov. (2002) 9:683-695.
33. SREEKUMAR A, NYATI MK, VARAMBALLY S et al.: Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. Cancer Res. (2001) 20:7585-7593.
34. TEMPLIN MF, STOLL D, SCHRENK M et al: Protein microarray technology. Trends Biotech. (2002) 4:160-166.
35. WULFKUHLE JD, PAWELETZ CP, STEEG PS, PETRICOIN EF 3RD, LIOTTA L: Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. Adv. Exp. Med. Biol (2003) 532:59-68.
36. YANAGISAWA K, SHYR Y, XU BJ et al: Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet (2003) 9382:433-439.
37. ZHU H, SNYDER M: Protein chip technology. Curr. Opin. Chem. Biol. (2003) 1:55-63.
38. CONRADS TP, FUSARO VA, ROSS S et al.: Multiple high-resolution serum proteomic features for ovarian detection. Endocr. Relat. Cancer (Submitted).
39. CHUNG CH, BERNARD PS, PEROU CM: Molecular portraits and the family tree of cancer. Nat. Genet. (2002) 32(Suppl.):533-540. Discussion of histological clustering, genetic microarrays and hierarchical dustering as related to cancer profiling.
40. CHUNG GG, KIELHORN EP, RIMM DL: Subjective differences in outcome are seen as a function of the immunohistochemical method used on a colorectal cancer tissue microarray. Clin. Colorectal Cancer (2002) 1(4):237-242.
41. NAM JM, THAXTON CS, MIRKIN CA: Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science (2003) 5641:1884-1886.
42. LIOTTA LA, CLAIR T: Cancer. Checkpoint for invasion. Nature (2000) 6784:287-288.
43. LIOTTA LA, KOHN EC: The microenvironment of the tumour-host interface. Nature (2001) 6835:375-379. Use of stromal therapy as a new strategy for cancer treatment.
44. LIOTTA LA: An attractive force in metastasis. Nature (2001) 6824:24-25.
45. HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2000) 1:57-70.
46. HUNTER T: Signaling - 2000 and beyond. Cell (2000) 1:113-127.
47. OLTVAI ZN, BARABASI AL: Systems biology. Life's complexity pyramid. Science (2002) 5594:763-764.
48. BLUME-JENSEN P, HUNTER T: Oncogenic kinase signalling. Nature (2001) 6835:355-365.
49. BOWDEN ET, BARTH M, THOMAS D, GLAZER PI, MUELLER SC: An invasion-related complex of cortactin, paxillin and PKCmu associates with invadopodia at sites of extracellular matrix degradation. Oncogene (1999) 31:4440-4449. Demonstrated correlation between invasion potential and matrix degradation of invasive breast cancer cells.
50. JEONG H, TOMBOR B, ALBERT R, OLTVAI ZN, BARABASI AL: The large-scale organization of metabolic networks: Nature (2000) 6804:651-654.
51. PETRICOIN EF, LIOTTA LA: Clinical applications of proteomics. J. Nutr. (2003) 7(Suppl.):2476S-2484S.
52. AHRAM M, FLAIG MJ, GILLESPIE JW et al.: Evaluation of ethanol-fixed, paraffin-embedded tissues for proteomic applications. Proteomics (2003) 4: 413-421.
53. CHARBONEAU L: Utility of reverse phase protein arrays: applications to signaling pathways and human body arrays. Brief Funct. Genomics Proteomics (2002) 3:305-315.
54. SIMONE NL, REMALEY AT, CHARBONEAU L et al.: Sensitive immunoassay of tissue cell proteins procured by laser capture microdissection. Am. J. Pathol. (2000) 2:445-452.
55. DARE TO, DAVIES HA, TURTON JA et al.: Application of surface-enhanced laser desorption/ionization technology to the detection and identification of urinary parvalbumin-alpha: a biomarker of compound-induced skeletal muscle toxicity in the rat. Electrophoresis (2002) 18:3241-3251.
56. FETSCH PA, SIMONE NL, BRYANT-GREENWOOD PK et al.: Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: potential for diagnostic applications. Am. J. Clin. Pathol. (2002) 6:870-876.
57. ISSAQ HJ, CONRADS TP, PRIETO DA, TIRUMALAI R, VEENSTRA TD: SELDI-TOF MS for diagnostic proteomics. Anal. Chem. (2003) 7:148A-155A.
58. HUTCHENS TW, YIP T-T: New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun. Mass Spectrom. (1993) 7:576-580.
59. MERCHANT M, WEINBERGER SR: Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis (2000) 6:1164-1177.
60. ISSAQ HJ, CONRADS TP, JANINI GM, VEENSTRA TD: Methods for fractionation, separation and profiling of proteins and peptides. Electrophoresis (2002) 17:3048-3061.
61. CONRADS TP, ZHOU M, PETRICOIN EF, LIOTTA LA, VEENSTRA TD: Cancer diagnosis using proteomic patterns. Expert Rev. Mol. Diagn. (2003) 4:411-420. Technical discussion of mass spectrometry profiling for ovarian and prostate cancer.
62. BATORFI J, YE B, MOK SC et al: Protein profiling of complete mole and normal placenta using ProteinChip analysis on laser capture microdissected cells. Gynecol. Oncol. (2003) 3:424-428. Identified three proteins differentially expressed in placental complete mole cells as compared with normal placenta.
63. HAMPEL H, GOERNITZ A, BUERGER K: Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein. Brain Res. Bull. (2003) 3:243-253.
64. YASUI Y, PEPE M, THOMPSON ML et al: A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. Biostatistics (2003) 3:449-463.
65. PETRICOIN EE, PAWELETZ CP, LIOTTA LA: Clinical applications of proteomics: proteomic pattern diagnostics. J. Mammary Gland Biol. Neoplasia (2002) 4:433-440.
66. LEWCZUK P, ESSELMANN H, MEYER M et al.: The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide. Rapid Commun. Mass Spectrom. (2003) 12:1291-1296.
67. BONK T, HUMENY A, SUTTER C et al.: Molecular diagnosis of familial adenomatous polyposis (FAP): genotyping of adenomatous polyposis coli (APC) alleles by MALDI-TOF mass spectrometry. Clin. Biochem. (2002) 2:87-92.
68. BONK T, HUMENY A, GEBERT J et al.: Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry-based detection of microsatellite instabilities in coding DNA sequences: a novel approach to identify DNA-mismatch repair-deficient cancer cells. Clin. Chem. (2003) 4:552-561.
69. CONRADS TP, ZHOU M, PETRICOIN EF 3RD, LIOTTA L, VEENSTRA TD: Cancer diagnosis using proteomic patterns. Expert Rev. Mol. Diagn (2003) 4:411-420.
70. JESSANI N, LIU Y, HUMPHREY M, CRAVATT BF: Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. Proc. Natl. Acad. Sci. USA (2002) 16:10335-10340.
71. IDEKER T, THORSSON V, RANISH JA et al.: Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science (2001) 5518:929-934.
72. PHIZICKY E, BASTIAENS PI, ZHU H, SNYDER M, FIELDS S: Protein analysis on a proteomic scale. Nature (2003) 6928:208-215.
73. TYERS M, MANN M: From genomics to proteomics. Nature (2003) 6928:193-197. Discussion of proteomic applications and of technological innovations and projects that may fulfil the profiling potential of proteomics.
74. WILSON DS, NOCK S: Recent developments in protein microarray technology. Angew Chem. Int. Ed. Engl. (2003) 5:494-500.
75. LAL SP, CHRISTOPHERSON RI, DOS REMEDIOS CG: Antibody arrays: an embryonic but rapidly growing technology. Drug Discov. Today (2002) 18(Suppl.): S 143-S 149.
76. MACBEATH G, SCHREIBER SL: Printing proteins as microarrays for high-throughput function determination. Science (2000) 5485:1760-1763.
77. PETACH H, GOLD L: Dimensionality is the issue: use of photoaptamers in protein microarrays. Curr. Opin. Biotechnol. (2002) 13(4):309-314.
78. SCHAEFERLING M, SCHILLER S, PAUL H et al.: Application of self-assembly techniques in the design of biocompatible protein microarray surfaces. Electrophoresis (2002) 18:3097-3105.
79. WENG S, GU K, HAMMOND PW et al: Generating addressable protein microarrays with Profusion covalent mRNA-protein fusion technology. Proteomics (2002) 1:48-57.
80. HUMPHERY-SMITH I, WISCHERHOFF E, HASHIMOTO R: Protein arrays for assessment of target selectivity. Drug Discov. World (2002) 1:17-27.
81. BACARESE-HAMILTON T, MEZZASOMA L, INGHAM C et al: Detection of allergen-specific IgE on microarrays by use of signal amplification techniques. Clin. Chem. (2002) 8:1367-1370.
82. BACARESE-HAMILTON T, GRAY J, CRISANTI A: Protein microarray technology for unraveling the antibody specificity repertoire against microbial proteomes. Curr. Opin. Mol. Ther. (2003) 3:278-284.
83. HUNYADY B, KREMPELS K, HARTA G, MEZEY E: Immunohistochemical signal amplification by catalyzed reporter deposition and its application in double immunostaining. J. Histochem. Cytochem. (1996) 12:1353-1362.
84. KING G, PAYNE S, WALKERF, MURRAY GI: A highly sensitive detection method for immunohistochemistry using biotinylated tyramine. J. Pathol. (1997) 2:237-241.
85. BOBROW MN, HARRIS TD, SHAUGHNESSY KJ, LITT GJ: Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays. J. Immunol. Methods (1989) 125(1-2):279-285.
86. BOBROW MN, SHAUGHNESSY KJ, LITT GJ: Catalyzed reporter deposition, a novel method of signal amplification. II. Application to membrane immunoassays. J. Immunol. Methods (1991) 137(1):103-112.
87. EMMERT-BUCK MR, BONNER RF, SMITH PD et al.: Laser capture microdissection. Science (1996) 5289:998-1001.
88. GILLESPIE JW, BEST CJ, BICHSEL VE et al.: Evaluation of non-formalin tissue fixation for molecular profiling studies. Am. J. Pathol. (2002) 2:449-457.
89. SIMONE NL, PAWELETZ CP, CHARBONEAU L, PETRICOIN EF 3RD, LIOTTA LA: Laser capture microdissection: beyond functional genomics to proteomics. Mol. Diagn. (2000) 4:301-307.
90. LIOTTA LA, KOHN EC: Cancer's deadly signature. Nat. Genet. (2003) 1: 10-11.
91. CARLISLE AJ, PRABHU VV, ELKAHLOUN A et al.: Development of a prostate cDNA microarray and statistical gene expression analysis package. Mol. Carcinog. (2000) 1:12-22.
92. HANASH S: Disease proteomics. Nature (2003) 6928:226-232. Discussion of genomic and proteomic technologies for disease profiling.
93. CHING CD MP, FUSARO V: Proteomic profiling if suspicious lung nodules: differentiating benign nodules from non-small cell lung cancer. In Proceedings of the 94th Annual Meeting of the American Association for Cancer Research. Washington DC (2003).
94. HOBBS SK, SHI G, HOMER R, HARSH G, ATLAS S, BEDNARSKI M: Magnetic resonance image guided proteomics of human glioblastoma multiforme. In: Proceedings of the 94th Annual Meeting of the American Association for Cancer Research. Washington DC (2003).
95. MILLER JC, ZHOU H, KWEKEL J et al.: Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics (2003) 1:56-63. Identified five serum biomarkers differentially expressed in prostate cancer as compared with a control group.